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contains one intrauterine and two vaginal catheters. The presence of 
an RTT during the vaginal impression is essential as support to the 
radiation oncologist. Based on the tumour topography representation, 
the RTT is able to manufacture a personalized mould adapted to the 
patient anatomy. The catheters positions are placed according to the 
physician recommendations. 
Before each treatment, the RTT performs quality controls on the 
afterloader. These controls, made under physicist responsibility, 
include all safety tests, verification of source positioning and 
agreement between air kerma rate calculated by the afterloader at 
the date of treatment for the source and the one measured at the 
date of calibration. 
In the operating room, the RTT checks the patient’s identity and is in 
charge of the patient installation. She prepares the medico-surgical 
instrumentation table and assists the radiation oncologist during the 
procedure. At the end of the implantation, she fills the technical 
documentation and gives it to nurses.  
Once the implantation is performed, the patient is transferred to the 
MRI scanner. With the help of a physician, the RTT inserts MRI 
compatible dummy sources into the catheters allowing a visualization 
of the intrauterine and vaginal positions of the sources. The 
delineation and the dosimetry are realised on MRI images. In this 
optimized 3D dosimetry, the RTT takes part in every step of the 
treatment. She creates the patient file in the treatment planning 
system (TPS),imports, checks the MRI images, and reconstructs the 
cervix applicator. Following the dosimetry validation, she records 
treatment parameters on a register and informs the patient on her 
treatment before it starts. 
In conclusion we have shown that the RTT is involved in every step of 
the cervix BT treatment. Her role is crucial in the treatment workflow 
and needs specifics skills to be accomplished.  In addition to 
versatility, the RTT needs a rigor, thoroughness, empathy and 
patience.  
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The question is whether PET response-adapted strategies can be 
devised to deliver radiation treatments to a selected group of 
patients. The backdrop of this persistent and sometimes emotional 
quest is complex but can be summarized as follows: first, combined 
modality treatments are superior to chemotherapy alone in terms of 
overall and progression-free survival, as demonstrated by a recent 
meta-analysis (1). Second, chemotherapy is very efficacious. Third, 
radiation treatments be get late complications such as second tumors 
and cardiovascular diseases. Fourth, the late effects of ABVD might 
have been grossly underestimated (2). PET response-adapted 
strategies can be implemented if PET predictive values are highly 
significant and reliable. Preliminary conclusions can be obtained from 
a small number of non randomized studies after completion of 
planned treatments. The negative predictive value (NPV) for the 
intermediary and end of treatment PET assessments was excellent (> 
95%). In contrast, the positive predictive value (PPV) was extremely 
low (15%-20%) and therefore systematic biopsies are always highly 
recommended to confirm the diagnosis. As, in all likelihood,the role 
of radiation therapy in advanced Hodgkin lymphoma will remain 
extremely reduced, we will focus on ongoing trials in early-stage 
Hodgkin lymphoma. Currently, there are 4 randomized trials and one 
non-randomized study. The relatively small Vancouver non-
randomized study suggested that radiotherapy could be avoided in 
approximately 80% of the patients with a negative PET after 2 ABVD 
cycles. Among the randomized trials, very favorable Hodgkin 
lymphoma patients were entered in 2 of them (mostly IA and IIA: 
GHSG and the UK Rapid trial). In two others (EORTC-LYSA-FIL H10, 
Euronet-PHLC-C1), all early stages were included. The preliminary 
results of the UK Rapid trial suggest that radiotherapy was not 
necessary in patients with a negative PET scan after 2 to 3 cycles of 
ABVD (75% of the patients). On the other hand, an interim analysis of 
the much larger H10 trial demonstrated that PET-negative patients 
after 2 ABVD cycles had a significantly higher risk of local recurrence 
or progression. The experimental arm with PET-negative patients was 
prematurely closed for further accrual. The very preliminary results of 
the ongoing Euronet trial, suggest that radiation treatments were not 
performed in a substantial number of PET-negative patients (only 40% 
of the French patients received radiation therapy: 26%, 41%, and 50% 
in the TG1, TG2, and TG3 groups respectively). 
Conclusions. Very preliminary results seem to suggest that an early 
PET response might provide a reliable basis for individualized 
response-adapted treatment strategies. However, the final results of 
the ongoing randomized trials should be awaited before drawing 
definite conclusions that may be applicable in clinical practice. 
Moreover, it must be emphasized that difficulties remain: the still 
persistent variability of PET assessment and the absence of a clear 
understanding of the underlying biological mechanisms of PET avidity. 
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Radiotherapy (RT) is the most effective single modality for local 
control of non Hodgkin lymphoma (NHL), and it is an important 
component of the treatment of many patients. The previously applied 
wide field and involved field techniques are no longer relevant, and 
have been replaced by defined volumes based on modern imaging and 
the ICRU concepts, the so-called involved site RT. Moreover, there is 
increasing evidence that the RT doses used in the past are higher than 
necessary for disease control. The goal of modern smaller field 
radiotherapy is to reduce both treatment volume and treatment dose 
whilst maintaining efficacy and minimising acute and late sequelae. 
B-cell lymphomas constitute 85-90 % of lymphomas in adults. The 
large majority expresses CD20 antigen. The development of anti-CD20 
antibodies, first Rituximab approved in 1997, significantly improved 
treatment results when added to standard chemotherapy for patients 
with advanced disease. The question is now if the role of RT in B-cell 
lymphomas has changed. 
Diffuse large B-cell lymphoma (DLBCL) is the most common 
aggressive lymphoma. For stage I-II patients without bulk or elevated 
LDH, standard treatment based on somewhat conflicting randomized 
trials was brief chemotherapy (3 cycles of CHOP) followed by IFRT. No 
randomized trial is available using R-CHOP, but retrospective analyses 
indicate that RT improves outcome also in this setting. For patients 
with risk factors 3 cycles of R-CHOP may not be enough. A positive 
PET-scan after R-CHOP has a low predictive value, and most PET+ 
cases achieve complete remission (CR) after RT. For advanced disease 
earlier studies showed benefit from RT in patients achieving a CR in 
some studies but not in others, whereas patients achieving only partial 
remission (PR) benefit from RT to residual masses. However, recent 
randomized studies in patients treated with Rituximab indicate that 
RT to initial bulk or extranodal disease, even in CR patients, improves 
outcome. Randomized evidence indicates that 30 Gy is a sufficient 
dose, at least in CR patients.  
Follicular lymphoma (FL) grade 1-2 is the most common indolent 
lymphoma. In early stage disease RT is still the only proven way for 
potential cure. Standard treatment is RT alone, and randomized 
evidence indicates that 24 Gy is a sufficient dose. Unfortunately, this 
treatment seems to be underused. For patients with advanced 
disease, if treatment is indicated, Rituximab with or without 
chemotherapy is given, but has not been shown to be curative. Low 
dose (2 Gy x 2) RT is an effective palliative treatment for locally 
symptomatic disease. 
Marginal zone lymphomas are indolent B-cell lymphomas, most often 
extranodal and localized. RT (24-30 Gy) is curative in the majority of 
localized cases, and is the preferred treatment (except for H. pylori 
positive gastric). Rituximab may be used if RT is contraindicated. 
Advanced disease is uncommon, no curative treatment exists, treated 
like FL. 
Mantle cell lymphomas are B-cell lymphomas with an aggressive 
behaviour. Very rarely these lymphomas are localized, and RT may be 
curative. No curative systemic treatment exists, and although 
Rituximab improves response rate and time to treatment failure it has 
little impact on survival. Advanced disease is incurable, but local 
palliative RT can be very effective. 
Primary cutaneous B-cell lymphomas are treated with local RT if 
solitary or regional. Only the aggressive type, DLBCL leg type, is also 
treated systemically (R-CHOP) for patients who can tolerate it. 
Patients with generalized disease are treated palliatively with 
Rituximab containing regimens, and local RT is given for palliation of 
symptoms.  
T-cell lymphomas are CD20 negative, and treatment is not influenced 
by the introduction of Rituximab. Most T-cell lymphomas present as 
advanced disease, RT has no role in the treatment except for 
palliation, and prognosis is poor. Exceptions are NK/T-cell lymphomas, 
cutaneous anaplastic large cell lymphomas, and mycosis fungoides, 
where RT is an important part of treatment.  
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Conclusion: RT remains an important modality in the treatment of 
NHL.  
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Background: Cure rates of patients with lymphoma have improved 
significantly over the last decades because of improved diagnostics, 
chemo(immuno)therapy and radiotherapy. There is, however, a large 
variety of late effects following treatment for lymphoma including 
decreased fertility, hormonal disturbances, pulmonary toxicity, soft 
tissue damage, second malignancies and cardiovascular diseases 
leading to considerable morbidity and excess mortality. The long-term 
burden of lymphoma treatment is determined by a combination of all 
late effects. Since (non) Hodgkin lymphoma ((N)HL) frequently occurs 
at relatively young ages, survivors are subject to the full spectrum of 
early and late side effects of therapy. Over time knowledge and 
awareness of late effects following cancer treatment have increased 
and treatment policies have been adapted accordingly. 
Improvement of treatment: Several randomized clinical trials have 
been performed to determine the role of radiation in lymphoma 
patientsespecially in HL patients. Radiation indication, target volume 
and dose have been subject of study. Since many important long-term 
complications (like second malignancies and cardiovascular toxicity) 
are related to radiation dose and volume, reduction of these 
treatment parameters are expected to ameliorate long-term toxicity 
(1,2). 
Reducing volume 
Over the last decades radiation volumes in lymphoma patients have 
changed considerably because of better knowledge in the spread of 
the disease through improved diagnostic possibilities and improved 
systemic treatments. 
In HL patients for instance radiation field-sizes have been reduced 
from subtotal-nodal or extended field to involved field or, more 
recently, involved site or involved node leading to smaller volumes of 
normal tissues exposed to significantly lower radiation doses. A word 
of caution, however: involved node radiotherapy should not be 
applied strictly when optimal pre-chemotherapy imaging is not 
available to the radiation oncologist. In this situation more generous 
margins should be used including the whole “site” where the 
lymphoma was located before chemotherapy. 
Furthermore, in early stage gastric lymphoma patients, total 
abdominal irradiation has been replaced by radiotherapy limited to 
the stomach and the surrounding lymph nodes using modern radiation 
techniques in selected patients only.  
Reducing dose 
For both HL and many subtypes of NHL systemic treatment options 
have improved significantly. These improvements have led to the 
possibility to reduce both radiation dose and volume while 
maintaining similar treatment outcomes (3). In the past generally 
doses up to 40-45 Gy in fractions of 2 Gy were used. Nowadays 
radiation doses in curative setting usually vary from 20 to 30 Gy and 
sometimes 36 Gy in fractions of 2 Gy. 
Technical improvements 
Deep inspiration breath hold 
In selected patients withmediastinal disease the use of deep 
inspiration breath hold and intensity modulated radiation therapy is 
expected to decrease exposure of the coronary arteries, heart, and 
lungs especially when the target volume is located in the upper part 
of the mediastinum (4).  
Proton therapy 
Another emerging technology is proton therapy. Proton therapy is 
associated with a substantial reduction in radiation dose to critical 
organs, such as the heart and lungs, and therefore has the potential to 
improve not only the therapeutic ratio, but also both event-free and 
overall survival.  
Conclusions 
Patient tailored radiotherapy inlymphoma patients using lower doses, 
smaller and better-defined radiation volumes than in the past, based 
on modern imaging and using conformal radiotherapy are expected to 
lead to an improved therapeutic ratio and decreased late effects. 
Further improvements are expected with the introduction of even 
more modern radiation techniques like deep inspirational breath hold. 
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Hypoxia is a cancer hallmark impacting tumor progression and 
treatment. From a biological standpoint, it promotes (i) a glycolytic 
switch formally corresponding to uncoupling glycolysis from oxidative 
phosphorylation and accelerating the glycolytic flux in order to fulfill 
the energetic and biosynthetic needs of cancer cells, (ii) an 
angiogenic switch, and (iii) a metastatic switch. From a therapeutic 
standpoint, hypoxia provides radioresistance notably because oxygen 
is molecularly involved in the stabilization of radiation-induced DNA 
damage. Among several interventions intended to improve oxygen 
availability to radiosensitize tumors, mathematical models indicate 
that those targeting tumor cell metabolism would be particularly 
efficient. Indeed, even a moderate inhibition of tumor cell respiration 
is predicted to significantly increase tumor oxygenation. 
Switching to a glycolytic metabolism is associated with the abundant 
release of lactate, the level of which positively correlates with tumor 
aggressiveness in patients. Although it was often considered as a mere 
glycolytic end-product, our work over the last 5 years showed that 
lactate is a direct tumor growth-promoting factor influencing tumor 
metabolism and angiogenesis. We first evidenced that lactate is a 
metabolic substrate preferred to glucose to fuel the oxidative 
activities of oxygenated tumor cells. This metabolic preference 
supports a metabolic symbiosis in which (i) hypoxic/glycolytic tumor 
cells produce lactate, (ii) oxygenated/oxidative tumor cells consume 
lactate sparing glucose, and (iii), consequently, glucose is made 
optimally available to fuel accelerated glycolysis in the hypoxic tumor 
cell compartment. Tumor-associated fibroblasts may constitute an 
additional source of lactate. We next found that lactate is also a 
signaling agent promoting tumor angiogenesis. Lactate oxidation to 
pyruvate, the LDH reaction, is shared by both metabolic and signaling 
paths. However, although pyruvate can be consumed in the 
mitochondrion to sustain oxidative ATP production, it can also 
competitively inhibit HIF-1 prolylhydroxylases even under normoxia. 
Lactate thereby activates the transcription factors HIF-1 in 
oxygenated tumor and endothelial cells and NF-κB in endothelial cells, 
thus triggering pro-angiogenic VEGF, bFGF and IL-8 signaling. We 
finally found that the metabolic and signaling use of lactate requires 
monocarboxylate transporter 1 (MCT1), a passive lactate-proton 
symporter located at the outer membrane of oxygenated tumor and 
endothelial cells where it facilitates lactate uptake. Targeting MCT1 
pharmacologically or with RNA interference first induced a glycolytic 
switch and, therefore, oxygen sparing in the oxygenated tumor cell 
compartment. It consequently eradicated the hypoxic tumor cell 
compartment by virtue of glucose starvation, whereas the remaining 
MCT1-positive tumor cells could be efficiently treated with X-ray 
radiotherapy as they were fully reoxygenated. MCT1 inhibition also 
blocked lactate signaling and tumor angiogenesis. 
Conclusively, our study shows (i) that lactate is a pleiotropic tumor 
growth-promoting factor, and (ii) that MCT1 inhibitors combine 
antimetabolic, radiosensitizing, and anti-angiogenic antitumor effects 
within a same molecule. A first MCT1 inhibitor, AZD-3965, is currently 
entering into clinical trials in UK. 
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Tumors similar to normal tissues contain extracellular matrix (ECM). 
Through integrin cell surface receptor binding, cells are integrated 
into multicellular structures and eventually tissues and organs. 
Different from normal tissues are the amount and organization of ECM 
in tumors giving rise to increased intratumoral pressure, tumor cell 
invasion, cancer stem cell niche development,and therapy resistance. 
Our understanding of adhesion-mediated tumor cell radio- and 
chemoresistance are still in its infancy. Evidently, integrin signaling 
activates key pro-survival determinants such as focal adhesion kinase, 
Akt, MAPK among many others, while the structural integrin-mediated 
cell-actin connection controls cell morphology including nuclear 
matrix and chromatin organization. Studies in normal cells such as 
fibroblasts or endothelial cells have revealed that all known cell 
functions ranging from cell survival to metabolism are co-regulated by 
